The Wu-Tang Clan rapper has recorded a video smackdown of pharma bad boy Shkreli.» Read More
Drug prices are expected to rise but the pace may slow, reports CNBC's Meg Tirrell.
KaloBios Pharmaceuticals, which fired chief executive Martin Shkreli earlier this month, filed for Chapter 11 bankruptcy on Tuesday.
CNBC's Meg Tirrell reports on biotech catalysts to come in 2016.
Michael Levesque, Moody's Investors Service SVP, lays out which pharmaceutical companies are best poised for a strong 2016.
CNBC's Meg Tirrell details three catalysts that could boost biotech in 2016.
Here's what to expect for the biotechnology sector in 2016, with CNBC's Meg Tirrell.
CNBC's Meg Tirrell reports on the ups and downs for Chimerix's experimental drug brincidofovir.
Barbara Ryan, Clermont Partners, shares her thoughts on innovation in the biotech space and the high cost of developing new drugs. And Scott Sperling, THL Partners, weighs in.
CNBC's Meg Tirrell takes a look at ways investors may be able to make money in the biotech sector next year.
KaloBios Pharmaceuticals said it has been notified by Nasdaq that its stock would be delisted using the exchange operator's "discretionary" authority.
KaloBios, a small company previously run by Martin Shkreli, has been notified that the Nasdaq plans to delist its shares.
Turing Pharmaceuticals said it is seeking a new chief executive to replace Martin Shkreli, who has been charged with fraud, and will cut jobs in a restructuring.
The biggest deal of 2015 to transform the M&A market was the $55 billion Charter-Time Warner deal, says Sachin Shah, special situations and merger arbitrage strategist at Albert Fried & Company.
The latest drug-price increases are just the tip of the iceberg, explains former Medtronic CEO Bill George.
Will the arrest of drug-company exec Martin Shkreli affect drug prices? Dan Eaton explains.
Bad-boy ex-pharmaceutical company CEO Martin Shkreli says fraud allegations against him are "baseless and without merit."
A bold federal effort to curb prescribing of painkillers may be faltering amid stiff resistance.
Former Turing CEO Martin Shkreli became one of the most hated people in America earlier this year after hiking the cost of a life-saving drug by more than 5,000 times—but that’s not what led to his arrest on securities fraud charges. CNBC’s Dan Mangan explains.
Martin Shkreli was suspected of faking a takeover bid for SeraCare — suspicions that were made known to federal authorities back in 2012, according to a source.
Turing Pharmaceuticals has appointed Chairman Ron Tilles to serve as interim CEO after Martin Shkreli was arrested, reports CNBC's Meg Tirrell.
Get the best of CNBC in your inbox